Skip to content
Newer NNRTI Agents in Clinical Practice episode artwork

Jul 11, 2023 27 min

Newer NNRTI Agents in Clinical Practice

from DKBmed Radio

Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for and in which ones should it be avoided? Join us as we discuss Newer NNRTI Agents in Clinical Practice with Dr. Darcy Wooten from the Division of Infectious Disease at the University of California, San Diego, in this issue of eHIV Review. Take our post-test to claim CME credits. To read a companion newsletter click here.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Newer NNRTI Agents in Clinical Practice

0:00 27:40

No transcript yet.

Requests help us decide what to transcribe next.

Share this episode

Similar podcasts

Gear Tasting Radio Radio ITS Have you ever analyzed why you've chosen the gear you have? Was it based on recommendations, or a true look into the skills to consider when making your selections? Look no further, Gear Tasting Radio is here with an in-depth look into the usage and philosophy behind the equipment in our lives.

Frequently asked questions

How long is this episode of DKBmed Radio?

This episode is 27 minutes long.

When was this DKBmed Radio episode published?

This episode was published on July 11, 2023.

Can I download this DKBmed Radio episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.